NCT02029573 (ART) is a Phase 2 clinical trial of Atorvastatin in Glioblastoma Multiforme, sponsored by King Fahad Medical City.

Who is sponsoring NCT02029573?

NCT02029573 is sponsored by King Fahad Medical City.

What drugs are being tested in NCT02029573?

Interventions in NCT02029573: Atorvastatin, Temozolomide, Radiotherapy.

What condition does NCT02029573 study?

NCT02029573 studies Glioblastoma Multiforme.

Is NCT02029573 still recruiting?

NCT02029573 is currently completed. Last updated 18 August 2017.

Last reviewed 2017-08-18 · How we verify

NCT02029573: ART

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Efficacy and Safety of Atorvastatin in Combination With Radiotherapy and Temozolomide in Glioblastoma

Completed Phase 2 Last updated 18 August 2017

What this trial tests

Phase 2 trial testing Atorvastatin in Glioblastoma Multiforme in 36 participants. Completed in 31 December 2016.

Timeline

1 January 2014

Primary endpoint
31 December 2016

31 December 2016

Quick facts

Lead sponsor	King Fahad Medical City
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	36
Start date	1 January 2014
Primary completion	31 December 2016
Estimated completion	31 December 2016
Sites	1 location across Saudi Arabia

Drugs / interventions tested

Atorvastatin (atorvastatin) — full drug profile →
Temozolomide (temozolomide) — full drug profile →
Radiotherapy — full drug profile →

Conditions studied

Glioblastoma Multiforme — all drugs for Glioblastoma Multiforme →

Sponsor

King Fahad Medical City — full company profile →

Who can join

Adults 18 to 70, any sex, with Glioblastoma Multiforme. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to explore the efficacy and safety of Atorvastatin in combination with multimodality therapy of concurrent radiotherapy plus temozolomide followed by adjuvant temozolomide in patients with newly diagnosed glioblastoma multiforme (GBM).The anticipated time on study treatment is until disease progression, and the target sample size is 32 individuals.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

The updated landscape of tumor microenvironment and drug repurposing.
Jin MZ, Jin WL. · · 2020 · cited 900× · PMID 32843638 · DOI 10.1038/s41392-020-00280-x
Current Challenges and Opportunities in Treating Glioblastoma.
Shergalis A, Bankhead A, Luesakul U, Muangsin N, et al · · 2018 · cited 612× · PMID 29669750 · DOI 10.1124/pr.117.014944
Statins: a repurposed drug to fight cancer.
Jiang W, Hu JW, He XR, Jin WL, et al · · 2021 · cited 311× · PMID 34303383 · DOI 10.1186/s13046-021-02041-2
Glioblastoma Therapy: Past, Present and Future.
Obrador E, Moreno-Murciano P, Oriol-Caballo M, López-Blanch R, et al · · 2024 · cited 147× · PMID 38473776 · DOI 10.3390/ijms25052529
A Systematic Review of Glioblastoma-Targeted Therapies in Phases II, III, IV Clinical Trials.
Cruz Da Silva E, Mercier MC, Etienne-Selloum N, Dontenwill M, et al · · 2021 · cited 99× · PMID 33918704 · DOI 10.3390/cancers13081795
Multicenter, Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Pravastatin Added to First-Line Standard Chemotherapy in Small-Cell Lung Cancer (LUNGSTAR).
Seckl MJ, Ottensmeier CH, Cullen M, Schmid P, et al · · 2017 · cited 91× · PMID 28240967 · DOI 10.1200/jco.2016.69.7391
The Innovative Potential of Statins in Cancer: New Targets for New Therapies.
Di Bello E, Zwergel C, Mai A, Valente S. · · 2020 · cited 84× · PMID 32626692 · DOI 10.3389/fchem.2020.00516
Repurposing non-oncology small-molecule drugs to improve cancer therapy: Current situation and future directions.
Fu L, Jin W, Zhang J, Zhu L, et al · · 2022 · cited 47× · PMID 35256933 · DOI 10.1016/j.apsb.2021.09.006

Verify or expand the search:

Other trials of Atorvastatin

Trials testing the same drug.

NCT07474649 — A Study of Bempedoic Acid/Ezetimibe/High-intensity Statin in Patients Without Cardiovascular Events · Phase 3 · not yet recruiting
NCT07462715 — Statins Against Bushfire Smoke · Phase 4 · not yet recruiting
NCT07530289 — A Clinical Study of Ulonivirine (MK-8507) With Atorvastatin and Metformin in Healthy Adults (MK-8507-018) · Phase 1 · not yet recruiting
NCT07534592 — A Study to Investigate the Effect of Elecoglipron on Rosuvastatin and Atorvastatin in Healthy Participants · Phase 1 · not yet recruiting
NCT07502001 — Influence of HDM1005 on Gastric Emptying and Pharmacokinetics of Metformin, Atorvastatin, Warfarin, and Digoxin · Phase 1 · not yet recruiting

Other recruiting trials for Glioblastoma Multiforme

Currently open trials in the same condition.

NCT06466031 — Application of FET-PET in Fusion With MRI in the Treatment of Glioblastoma Multiforme [TYR-GLIO] · NA · recruiting
NCT06333899 — Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion · EARLY_PHASE1 · recruiting
NCT05956821 — Treatment of Relapsed/Refractory Intracranial Glioma in Patients Under 22 Years of Age · Phase 1, PHASE2 · recruiting
NCT06496971 — A Prospective Pivotal Study to Evaluate the Efficacy and Safety of Avastin® Bevacizumab (BEV) With or Without Microbubbl · Phase 3 · recruiting
NCT06329570 — Safety and Efficacy of Bevacizumab in Combination With NaviFUS System for the Treatment of Recurrent Glioblastoma Multif · Phase 1, PHASE2 · recruiting

Other King Fahad Medical City trials

Trials by the same sponsor.

NCT06416202 — Closed Loop Pumps vs. Traditional Open Loop Pumps in Managing Blood Glucose Levels in T1DM Patients Fasting in Ramadan. · NA · active not recruiting
NCT06945744 — Carbohydrate Counting and Bolus Calculator Mobile Application Improves Time in Range in Adults With Type 1 Diabetes · NA · completed
NCT07045506 — Estimating Umbilical Venous Catheter Insertion Depth in Newborns Using Weight or Body Measurements: A Multicenter Random · NA · completed
NCT04386525 — Omega 3 and Ischemic Stroke; Fish Oil as an Option · Phase 4 · unknown
NCT04351425 — Early Weaning of Preterm Newborn From Incubator to Cot at 1400 Grams · NA · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02029573 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by King Fahad Medical City
Last refreshed: 18 August 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02029573.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing